ESPR News Alert Esperion Therapeutics Inc (ESPR) 35.97 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Esperion Therapeutics Inc (ESPR) 35.97 $ESPR

Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST

NICK: 14.80 (+0.20), JRJC: 5.81 (-0.11), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), VNDA: 14.69 (+1.11), EPAX: 2.46 (-0.08), FES: 1.19 (-0.01), NQ: 4.32 (-0.36), TECU: 3.59 (-0.14), VRML: 1.81 (+0.15), MYOS: 7.10 (+0.07), PME: 2.00 (+0.10), ESPR: 35.97 (-0.08), ALNY: 93.52 (+0.97), IDSA: 4.52 (-0.18), PRLS: 6.85 (+0.01), ACHN: 13.06 (+1.22), SKYS: 11.05 (-0.95), RCPT: 122.05 (+4.05), AGIO: 109.67 (+2.45)

Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 104.59 (+0.31), ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)

CORRECTION - Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 7:05PM CST
In a release issued under the same headline earlier today by The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) the ticker and exchange for Esperion Therapeutics, Inc. should read (Nasdaq:ESPR) (sted Nasdaq:EXPR).
ESPR: 35.97 (-0.08), NDAQ: 48.74 (-0.40)

Can the Rally in Esperion Therapeutics (ESPR) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:21AM CST
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue?
ESPR: 35.97 (-0.08)

Surging Earnings Estimates Signal Good News for Esperion Therapeutics (ESPR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:50AM CST
Esperion Therapeutics is seeing solid activity on the earnings estimate revision and has decent short-term momentum. The stock has also started to move higher lately, adding 20.5% over the past four weeks.
ESPR: 35.97 (-0.08)

InsiderInsights.com Daily Round Up 11/19/14: CJES, MGPI, PSX, STAA
InsiderInsights - at Seeking Alpha - Thu Nov 20, 1:58AM CST

PSX: 72.10 (-0.46), CJES: 13.39 (-0.29), CPS: 58.76 (+0.60), BAH: 27.08 (-0.03), MRD: 18.64 (-0.53), MGPI: 16.53 (+0.28), GOOG: 528.77 (-1.82), MAS: 25.17 (-0.14), ESPR: 35.97 (-0.08), NOW: 69.69 (+0.12), LNKD: 231.83 (+0.34), SCTY: 56.76 (+0.92), STAA: 9.11 (-0.08), AINC: 89.50 (+2.50), FANG: 60.18 (-1.51), SFXE: 4.42 (+0.04), APD: 148.58 (unch), CSCO: 28.30 (+0.05), FOLD: 7.94 (+0.06)

Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), REGN: 400.12 (+6.07)

Can The Uptrend Continue for Esperion (ESPR)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:38AM CST
Can The Uptrend Continue for Esperion (ESPR)?
ESPR: 35.97 (-0.08)

Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.29 (+1.79), ESPR: 35.97 (-0.08), BIOD: 1.36 (-0.04)

Esperion up on Merck trial results
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:20PM CST

ESPR: 35.97 (-0.08)

Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Stifel 2014 Healthcare Conference in New York City, N.Y. on Wednesday, November 19, 2014 at 11:30 a.m. Eastern Time.
ESPR: 35.97 (-0.08)

Esperion Therapeutics to Host and Webcast Live Investor Event
Business Wire - Tue Nov 11, 3:30PM CST
--Webcast on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30 p.m. Eastern Time
ESPR: 35.97 (-0.08)

Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25PM CST

ESPR: 35.97 (-0.08)

Esperion Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:27PM CST

ESPR: 35.97 (-0.08)

Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014.
ESPR: 35.97 (-0.08)

Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Wed Nov 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 8:00 a.m. Mountain Time/10:00 a.m. Eastern Time.
ESPR: 35.97 (-0.08)

Esperion Therapeutics to Provide Third Quarter 2014 Results
Business Wire - Mon Nov 03, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results for the third quarter 2014. The webcast will take place on Monday, November 10, 2014 at 4:30 p.m. Eastern Time.
ESPR: 35.97 (-0.08)

InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT

LDRH: 33.82 (-0.26), BKCC: 8.15 (unch), RDEN: 20.56 (-0.24), AGCO: 45.46 (-0.81), MLNK: 3.69 (-0.01), ATRA: 28.00 (+0.41), DHR: 86.79 (-0.27), SHLD: 32.56 (-0.37), GOOG: 528.77 (-1.82), HPQ: 40.54 (+0.18), ATNI: 67.50 (-0.20), PM: 83.15 (-0.15), ESPR: 35.97 (-0.08), FMI: 23.99 (-0.10), LNKD: 231.83 (+0.34), MAT: 30.22 (-0.16), SYK: 96.00 (-0.61), IPGP: 75.14 (+0.30)

Multiple Insiders of Esperion Therapeutics, Inc. (ESPR)-NasdaqGM bought Shares of ESPR
M2 - Wed Oct 22, 7:32AM CDT
Reported by InsiderCow.com at 2014-10-21 12:20:02 ET
ESPR: 35.97 (-0.08)

Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
Business Wire - Tue Oct 21, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the closing of its follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock. This exercise brings the net proceeds in the offering to $91.6 million, after deducting underwriting discounts and commissions and expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through completion of the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 35.97 (-0.08), JPM: 62.48 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 97

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 51

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 88

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

DexCom Faces Class Action Lawsuit Over Securities Fraud Claims

Updated Category News Views 104

Overview of the Class Action Against DexCom, Inc. Investors in DexCom, Inc. are currently navigating important developments as a class action lawsuit has been filed. This legal action involves serious allegations of securities fraud against the company. Shareholders who have purchased DexCom securities may be affected, raising important questions about financial integrity...

Continue Reading
Amaroq Minerals Announces AGM Results and Future Directions

Updated Category News Views 209

Amaroq Minerals Ltd. Annual General Meeting Results Amaroq Minerals Ltd. is proud to share the results from its recent Annual General Meeting (AGM), reflecting a robust commitment from shareholders in shaping the future direction of the company. Held in a welcoming atmosphere, the event focused on critical decisions that underscore the corporation's strategic objectives...

Continue Reading
Explore the Theme of Connection and Creation at CIFF 2026

Updated Category News Views 254

Exciting New Developments at CIFF 2026 CIFF, the China International Furniture Fair, is gearing up for its 57th edition in March 2026. With a fresh theme, "CONNECT • CREATE", the event reflects the dynamic landscape of the furniture industry. The fair will facilitate exceptional connections within the furniture supply chain, including production, distribution, and...

Continue Reading
SpaceX's Starship to Showcase Advanced Starlink Technologies

Updated Category News Views 545

SpaceX's Latest Milestone in Satellite Technology Elon Musk's company, SpaceX, is gearing up for an exciting upcoming test flight of its Starship launch vehicle. The mission's highlight is the planned deployment of 10 model Starlink satellites, marking a significant step in demonstrating SpaceX's prowess in the satellite launch industry. The Innovative Starlink Satellites...

Continue Reading
DATAMYTE Introduces AI Efficiency in Mobile Inspections for APQP

Updated Category News Views 354

Transforming Quality Inspections with AI at DATAMYTE DATAMYTE, a leader in manufacturing technology, is truly reshaping the way inspections are conducted in the industry. By utilizing its innovative DIGITAL CLIPBOARD mobile platform alongside the powerful DATAMYTE GPT Artificial Intelligence System, the company is redefining the manual processes traditionally associated...

Continue Reading